Abstract
Naturally occurring regulatory T cells (nTregs; CD4+CD25+Foxp3+) are capable of suppressing the chronic inflammation observed in a variety of different animal models of autoimmune and chronic inflammatory diseases such as inflammatory bowel diseases, diabetes, and arthritis. A major limitation in exploring how and where nTregs exert their suppression in vivo is the relative paucity of these regulatory cells. Although several laboratories have described different methods to expand flow-purified nTregs or convert conventional/naïve T cells (CD4+Foxp3−) to Foxp3-expressing “induced” Tregs (iTregs; CD4+Foxp3+) ex vivo, we have found that many of these approaches are encumbered with their own limitations. Therefore, we sought to develop a relatively simple ex vivo method to generate large numbers of Foxp3-expressing iTregs that can be used to evaluate their trafficking properties, suppressive activity, and therapeutic efficacy in a mouse model of chronic gut inflammation in vivo. We present a detailed protocol demonstrating that polyclonal activation of conventional CD4+ T cells in the presence of IL-2, TGFβ, and all trans retinoic acid induces >90% conversion of these T cells to Foxp3-expressing iTregs as well as promotes a three- to fourfold increase in proliferation following a 4-day incubation period in vitro. This protocol enhances modestly the surface expression of the gut-homing adhesion molecule CCR9 but not α4β7. Furthermore, we provide preliminary data demonstrating that these iTregs are significantly more potent at suppressing T-cell activation in vitro and are equally effective as freshly isolated nTregs at attenuating chronic colitis in vivo. Finally, we report that this protocol has the potential to generate 30–40 million iTregs from one healthy mouse spleen.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Sakaguchi, S. et al. (2006) Foxp3+ CD25+ CD4+ natural regulatory T cells in dominant self-tolerance and autoimmune disease. Immunol. Rev. 212, 8–27.
Scheffold, A., Murphy, K.M. & Hofer, T. (2007) Competition for cytokines: T(reg) cells take all. Nat. Immunol. 8, 1285–1287.
Uhlig, H.H. et al. (2006) Characterization of Foxp3+CD4+CD25+ and IL-10-secreting CD4+CD25+ T cells during cure of colitis. J. Immunol. 177, 5852–5860.
Vignali, D.A., Collison, L.W. & Workman, C.J. (2008) How regulatory T cells work. Nat. Rev. Immunol. 8, 523–532.
Earle, K.E. et al. (2005) In vitro expanded human CD4+CD25+ regulatory T cells suppress effector T cell proliferation. Clin. Immunol. 115, 3–9.
Tang, Q. et al. (2004) In vitro-expanded antigen-specific regulatory T cells suppress autoimmune diabetes. J. Exp. Med. 199, 1455–1465.
Battaglia, M., Stabilini, A. & Roncarolo, M.G. (2005) Rapamycin selectively expands CD4+CD25+FoxP3+ regulatory T cells. Blood 105, 4743–4748.
Taylor, P.A., Lees, C.J. & Blazar, B.R. (2002) The infusion of ex vivo activated and expanded CD4(+)CD25(+) immune regulatory cells inhibits graft-versus-host disease lethality. Blood 99, 3493–3499.
Chen, W. et al. (2003) Conversion of peripheral CD4+. J. Exp. Med. 198, 1875–1886.
Benson, M.J., Pino-Lagos, K., Rosemblatt, M. & Noelle, R.J. (2007) All-trans retinoic acid mediates enhanced T reg cell growth, differentiation, and gut homing in the face of high levels of co-stimulation. J. Exp. Med. 204, 1765–1774.
Fantini, M.C., Dominitzki, S., Rizzo, A., Neurath, M.F. & Becker, C. (2007) In vitro generation of CD4+ CD25+ regulatory cells from murine naive T cells. Nat. Protoc. 2, 1789–1794.
Kang, S.G., Lim, H.W., Andrisani, O.M., Broxmeyer, H.E. & Kim, C.H. (2007) Vitamin A metabolites induce gut-homing FoxP3+ regulatory T cells. J. Immunol. 179, 3724–3733.
Mucida, D. et al. (2007) Reciprocal TH17 and regulatory T cell differentiation mediated by retinoic acid. Science 317, 256–260.
Fontenot, J.D. et al. (2005) Regulatory T cell lineage specification by the forkhead transcription factor foxp3. Immunity 22, 329–341.
Zheng, S.G., Wang, J.H., Wang, P., Gray, J.D. & Horwitz, D.A. (2007) IL-2 is essential for TGF-beta to convert naive CD4(+)CD25(−) cells to CD25(+)Foxp3(+) regulatory T cells and for expansion of these cells. J. Immunol. 178, 2018–2027.
Sun, C.M. et al. (2007) Small intestine lamina propria dendritic cells promote de novo generation of Foxp3 T reg cells via retinoic acid. J. Exp. Med. 204, 1775–1785.
Hill, J.A. et al. (2008) Retinoic acid enhances Foxp3 induction indirectly by relieving inhibition from CD4+CD44hi Cells. Immunity 29, 758–770.
Mucida, D. et al. (2009) Retinoic acid can directly promote TGF-beta-mediated Foxp3(+) Treg cell conversion of naive T cells. Immunity 30, 471–472.
Thornton, A.M. & Shevach, E.M. (1998) CD4+CD25+ immunoregulatory T cells suppress polyclonal T cell activation in vitro by inhibiting interleukin 2 production. J. Exp. Med. 188, 287–296.
Ostanin, D.V. et al. (2009) T cell transfer model of chronic colitis: concepts, considerations, and tricks of the trade. Am. J. Physiol. Gastrointest. Liver Physiol. 296, G135–G146.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2010 Humana Press
About this protocol
Cite this protocol
Karlsson, F., Robinson-Jackson, S.A., Gray, L., Zhang, S., Grisham, M.B. (2010). Ex Vivo Generation of Regulatory T Cells: Characterization and Therapeutic Evaluation in a Model of Chronic Colitis. In: Cuturi, M., Anegon, I. (eds) Suppression and Regulation of Immune Responses. Methods in Molecular Biology, vol 677. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-60761-869-0_4
Download citation
DOI: https://doi.org/10.1007/978-1-60761-869-0_4
Published:
Publisher Name: Humana Press, Totowa, NJ
Print ISBN: 978-1-60761-868-3
Online ISBN: 978-1-60761-869-0
eBook Packages: Springer Protocols